CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics
- 1 January 2011
- journal article
- review article
- Published by Elsevier BV in Journal of Pharmaceutical Sciences
- Vol. 100 (1), 38-52
- https://doi.org/10.1002/jps.22243
Abstract
No abstract availableThis publication has 152 references indexed in Scilit:
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Development of Lipidoid–siRNA Formulations for Systemic Delivery to the LiverMolecular Therapy, 2009
- Biological Barriers to Therapy with Antisense and siRNA OligonucleotidesMolecular Pharmaceutics, 2009
- A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA DeliveryMolecular Pharmaceutics, 2009
- Nonviral Methods for siRNA DeliveryMolecular Pharmaceutics, 2008
- Nanoparticle size and surface properties determine the protein corona with possible implications for biological impactsProceedings of the National Academy of Sciences of the United States of America, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticlesJournal of Controlled Release, 2008
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences of the United States of America, 2007
- Synthesis and Evaluation of Bivalent NDP-α-MSH(7) Peptide Ligands for Binding to the Human Melanocortin Receptor 4 (hMC4R)Bioconjugate Chemistry, 2007